¼¼°èÀÇ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå
Chemotherapy-Induced Neutropenia Treatment
»óǰÄÚµå : 1551462
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 381 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀåÀº 2030³â±îÁö 6¾ï 5,990¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î Àü¸ÁÀÔ´Ï´Ù.

2023³â¿¡ 5¾ï 6,690¸¸ ´Þ·¯·Î ÃßÁ¤µÈ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀåÀº 2030³â¿¡´Â 6¾ï 5,990¸¸ ´Þ·¯¿¡ À̸£·¶À¸¸ç, ºÐ¼® ±â°£ ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 2.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °ú¸³±¸ ÄÝ·Î´Ï ÀÚ±Ø ÀÎÀÚ ¿ä¹ý(Granulocyte Colony-Stimulating Factors Therapy)Àº º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÌ¸ç º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 3.3%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ Á¾·á±îÁö 2¾ï 5,920¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç×»ýÁ¦ Ä¡·á ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 1.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 5,450¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç Áß±¹Àº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 4.7%·Î ¼ºÀå ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹Ì±¹ÀÇ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀåÀº 2023³â 1¾ï 5,450¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°èÀÇ 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 3,120¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 4.7%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº °¢°¢ 0.5%¿Í 1.6%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 1.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á½ÃÀå- ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõÀº ¹«¾ùÀΰ¡?

È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõÀº ¾Ï Ä¡·áÀÇ ½É°¢ÇÑ ºÎÀÛ¿ëÀ̸ç, °¨¿°°ú ½Î¿ì´Âµ¥ Áß¿äÇÑ ¹éÇ÷±¸ÀÇ ÀÏÁ¾ÀΠȣÁß±¸ÀÇ ¼ö¸¦ °¨¼Ò½ÃÅ´À¸·Î½á ¸é¿ª°è¸¦ ÇöÀúÇÏ°Ô ¼Õ»ó½Ãŵ´Ï´Ù. È£Áß±¸°¨¼ÒÁõÀº È­Çпä¹ýÀÌ ±Þ¼ÓÈ÷ ºÐ¿­ÇÏ´Â ¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î Çϱ⠶§¹®¿¡ ¹ß»ýÇÏÁö¸¸, ÀÌ´Â ¾Ï¼¼Æ÷¿Í È£Áß±¸¸¦ »ý»êÇÏ´Â °ñ¼ö µî °Ç°­ÇÑ ¼¼Æ÷ÀÇ ¾çÂÊ Æ¯Â¡ÀÔ´Ï´Ù. ±× °á°ú È£Áß±¸ÀÇ ¼ö°¡ °¨¼ÒÇϱ⠶§¹®¿¡ ȯÀÚ´Â °¨¿°¿¡ ¸Å¿ì °É¸®±â ½±°í ½Å¼ÓÇÏ°Ô ´ëóÇÏÁö ¾ÊÀ¸¸é »ý¸íÀ» À§ÇùÇÏ°Ô µË´Ï´Ù. °¨¿°ÁõÀÇ ¸®½ºÅ©´Â È£Áß±¸°¨¼ÒÁõÀÇ ÁßÁõµµ°¡ ³ôÀ»¼ö·Ï ³ô¾ÆÁö°í, °æÁõÀÇ °¨¿°ÁõÀÌ¶óµµ ½É°¢ÇÑ ÇÕº´ÁõÀ̳ª ÀÔ¿ø, ¾Ï Ä¡·áÀÇ Áö¿¬À¸·Î À̾îÁú °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. µû¶ó¼­ È­Çпä¹ýÀ¸·Î È£Áß±¸°¨¼ÒÁõÀ» °ü¸®ÇÏ´Â °ÍÀº ¾Ï ȯÀÚÀÇ °Ç°­°ú ¾ÈÀüÀ» À¯ÁöÇÏ´Â µ¥ ÇʼöÀûÀÌ¸ç ¾Ï È¯ÀÚ´Â Ä¡·á Áß´ÜÀ» ÁÙÀ̰í ÇÕº´Áõ À§Çè °¨¼ÒÇϸ鼭 Ä¡·á ¿ä¹ýÀ» °è¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.

È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·áÀÇ ÇöÀç Àü·«°ú °úÁ¦¶õ?

È­Çпä¹ý¿¡ ÀÇÇÑ È£Áß±¸°¨¼ÒÁõ¿¡ ´ëÇÑ Ä¡·á Àü·«Àº ÁÖ·Î °¨¿°ÀÇ ¿¹¹æ°ú ȯÀÚÀÇ ¸é¿ª°èÀÇ Áö¿ø¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. °¡Àå ÈçÇÑ Á¢±Ù¹ýÀº ÇÊ±Û¶ó½ºÆÀ, Æä±×ÇÊ ±Û¶ó½ºÆÀ, ¹ÙÀÌ¿À½Ã¹Ð·¯¿Í °°Àº °ú¸³±¸ ÄÝ·Î´Ï ÀÚ±Ø ÀÎÀÚ(G-CSF)ÀÇ »ç¿ëÀ̸ç, À̵éÀº °ñ¼ö¿¡¼­ È£Áß±¸ÀÇ »ý»êÀ» ÀÚ±ØÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº ÀϹÝÀûÀ¸·Î È£Áß±¸ °¨¼Ò ±â°£°ú ÁßÁõµµ¸¦ ÁÙÀ̱â À§ÇØ È­ÇÐ ¿ä¹ý ÈÄ ÁÖ»ç·Î Åõ¿©µË´Ï´Ù. Ç×»ýÁ¦ÀÇ ¿¹¹æ Åõ¿©´Â ÁßÁõ È£Áß±¸ °¨¼ÒÁõ ȯÀÚÀÇ °¨¿°À» ¿¹¹æÇÏ´Â µ¥ »ç¿ëµÇ´Â ¶Ç ´Ù¸¥ Àü·«ÀÔ´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ Ä¡·á¿¡ ¾î·Á¿òÀÌ ¾ø´Â °ÍÀº ¾Æ´Õ´Ï´Ù. G-CSF ¿ä¹ýÀº ºñ½Î°í °ñÅë°ú µå¹°°Ô ºñÀå ÆÄ¿­°ú °°Àº ºÎÀÛ¿ëÀ» µ¿¹ÝÇÕ´Ï´Ù. ¶ÇÇÑ ÇÕº´ÁõÀ» ÇÇÇϱâ À§Çؼ­´Â G-CSF Åõ¿© ½ÃÁ¡°ú º¹¿ë·®À» ½ÅÁßÇÏ°Ô °ü¸®ÇؾßÇÕ´Ï´Ù. ¶ÇÇÑ ¸ðµç ȯÀÚ°¡ ÀÌ·¯ÇÑ Ä¡·á¿¡ ¹ÝÀÀÇÏ´Â °ÍÀº ¾Æ´Ï¸ç ÀÔ¿ø ¹× ÁýÁß Ä¡·á°¡ ÇÊ¿äÇÑ È£Áß±¸ °¨¼ÒÁõÀÇ ¿¡ÇǼҵ带 °æÇèÇϴ ȯÀÚµµ ÀÖ½À´Ï´Ù. Ç×»ýÁ¦¿¡ ´ëÇÑ ³»¼ºÀÇ ¹ß´Þµµ Áß¿äÇÑ °úÁ¦À̸ç, »õ·Î¿î Ä¡·á Á¢±Ù¹ý°ú º¸´Ù ¸ÂÃã Ä¡·á Àü·«ÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

°Ç°­ °ü¸® Á¦°ø¾÷ü´Â ÀÓ»ó ÇöÀå¿¡¼­ È­ÇÐ ¿ä¹ý À¯¹ß È£Áß±¸ °¨¼ÒÁõÀ» ¾î¶»°Ô °ü¸®Çմϱî?

ÀÓ»ó ÇöÀå¿¡¼­ È­Çпä¹ýÀ» À¯¹ßÇϴ ȣÁß±¸°¨¼ÒÁõÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÏ·Á¸é Àû±ØÀûÀÎ ¸ð´ÏÅ͸µ, ½Ã±âÀûÀýÇÑ °³ÀÔ, ȯÀÚ ±³À°À» °áÇÕÇØ¾ß ÇÕ´Ï´Ù. Á¾¾çÀÇ»ç´Â ÀϹÝÀûÀ¸·Î È­ÇÐ ¿ä¹ýÀ» ½ÃÀÛÇϱâ Àü¿¡ ¿¬·É, Àü½Å °Ç°­ »óÅÂ, ƯÁ¤ È­ÇÐ ¿ä¹ýÀÇ À¯Çü°ú ¿ë·®°ú °°Àº ¿äÀÎÀ» °í·ÁÇÏ¿© ȯÀÚÀÇ È£Áß±¸ °¨¼ÒÁõÀÇ À§ÇèÀ» Æò°¡ÇÕ´Ï´Ù. À§ÇèÀÌ ³ôÀº ȯÀÚ¿¡°Ô´Â G-CSFÀÇ ¿¹¹æÀû Åõ¿©°¡ ±ÇÀåµË´Ï´Ù. Ä¡·áÇÏ´Â µ¿¾È Á¤±âÀû ÀÎ Ç÷¾× °Ë»ç·Î È£Áß±¸ ¼ö¸¦ ÃßÀûÇϰí È£Áß±¸ °¨¼ÒÀÇ Á¶±â ¡Èĸ¦ °¨ÁöÇÏ¿© ȯÀÚ¸¦ÁÖÀÇ ±í°Ô °üÂûÇÕ´Ï´Ù. È£Áß±¸ °¨¼Ò°¡ ¹ßÇöµÇ´Â °æ¿ì È£Áß±¸ ¼ö°¡ ȸº¹µÉ ¶§±îÁö È­Çпä¹ýÀÇ º¹¿ë·®À» ÁÙÀ̰ųª ÈÄ¼Ó »çÀÌŬÀ» Áö¿¬½ÃÄÑ Ä¡·á °èȹÀ» Á¶Á¤ÇÕ´Ï´Ù. ÁÁÀº À§»ý ½À°ü, °¨¿° ¿äÀο¡ ´ëÇÑ ³ëÃâ ¹æÁö, °¨¿°ÀÇ Ãʱâ ¡ÈÄ ÀνĿ¡ ´ëÇÑ È¯ÀÚ ±³À°°ú °°Àº °¨¿° ¿¹¹æ Á¶Ä¡´Â Ä¡·áÀÇ Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù. ¶ÇÇÑ, ¹ß¿­¼º È£Áß±¸°¨¼ÒÁõ(¹ß¿­ ¹× È£Áß±¸ ¼ö °¨¼Ò¸¦ Ư¡À¸·Î ÇÏ´Â ±ä±ÞÀÇ·á)ÀÇ °æ¿ì, »óŸ¦ °ü¸®Çϰí Ãß°¡ ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§ÇØ ½Å¼ÓÇÑ ÀÔ¿ø°ú Àû±ØÀûÀÎ Ç×»ýÁ¦ Ä¡·á°¡ ÇÊ¿äÇÕ´Ï´Ù.

È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº?

È­Çпä¹ý À¯¹ß¼º È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¼¼°èÀÇ ¾Ï ÀÌȯÀ² Áõ°¡, È¿°úÀûÀÎ ¾Ï Ä¡·á ¹× ÁöÁö¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. È­Çпä¹ý°ú Ç¥Àû¾Ï Ä¡·áÀÇ Áøº¸´Â »ýÁ¸À²À» Çâ»ó½ÃŰ´Â ÇÑÆí È£Áß±¸°¨¼ÒÁõÀÇ ¹ß»ý·ü Áõ°¡¿¡µµ ±â¿©Çϰí ÀÖ¾î º¸´Ù °ß°íÇÑ °ü¸® ¼Ö·ç¼ÇÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ µµÀÔÀº G-CSF ¿ä¹ýÀ» ´õ¿í Ä£¼÷Çϰí ÇÕ¸®ÀûÀ¸·Î ¸¸µé¾î ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³ÀÎÈ­µÈ ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡´Â °³º° ȯÀÚÀÇ À§Çè ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó È£Áß±¸ °¨¼ÒÁõÀÇ °ü¸®¸¦ ÃÖÀûÈ­ÇÏ´Â ¸ÂÃãÇü Ä¡·á ¿ä¹ýÀÇ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ÇコÄɾîÀÇ ÀÎÇÁ¶ó Á¤ºñ¿Í °íµµÀÇ ¾Ï Ä¡·á¿¡ÀÇ ¾×¼¼½ºÀÇ Çâ»óµµ, G-CSF¿Í °°Àº ÁöÁö ¿ä¹ýÀ» Æ÷ÇÔÇÑ Á¾ÇÕÀûÀÎ ¾Ï Ä¡·á¸¦ ¹ÞÀ» ¼ö Àִ ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó, ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÕ´Ï´Ù. °Ô´Ù°¡ È£Áß±¸°¨¼ÒÁõ Ä¡·áÀÇ È¿´É°ú ¾ÈÀü¼º Çâ»óÀ» ¸ñÇ¥·Î ÇÏ´Â ¿¬±¸°³¹ßÀÌ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ÀÌ Áß¿äÇÑ È­Çпä¹ýÀÇ ºÎÀÛ¿ëÀ» º¸´Ù Àß °ü¸®Çϱâ À§ÇÑ »õ·Î¿î Èñ¸ÁÀÌ °¡Á®¿Â °ÍÀ¸·Î, ½ÃÀåÀº ´õ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñÀÇ 48»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Chemotherapy-Induced Neutropenia Treatment Market to Reach US$659.9 Million by 2030

The global market for Chemotherapy-Induced Neutropenia Treatment estimated at US$566.9 Million in the year 2023, is expected to reach US$659.9 Million by 2030, growing at a CAGR of 2.2% over the analysis period 2023-2030. Granulocyte Colony-Stimulating Factors Therapy, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$259.2 Million by the end of the analysis period. Growth in the Antibiotic Therapy segment is estimated at 1.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$154.5 Million While China is Forecast to Grow at 4.7% CAGR

The Chemotherapy-Induced Neutropenia Treatment market in the U.S. is estimated at US$154.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$131.2 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.5% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Chemotherapy-Induced Neutropenia Treatment Market - Key Trends and Drivers Summarized

What Is Chemotherapy-Induced Neutropenia, and Why Is It a Major Concern?

Chemotherapy-induced neutropenia is a severe side effect of cancer treatment that significantly compromises the immune system by reducing the number of neutrophils, a type of white blood cell crucial for fighting infections. Neutropenia occurs because chemotherapy targets rapidly dividing cells, a characteristic of both cancerous cells and healthy cells such as those in the bone marrow that produce neutrophils. The resulting decrease in neutrophil count leaves patients highly vulnerable to infections, which can become life-threatening if not promptly addressed. The risk of infection increases with the severity of neutropenia, and even minor infections can lead to serious complications, hospitalizations, and delays in cancer treatment. Therefore, managing chemotherapy-induced neutropenia is essential for maintaining the health and safety of cancer patients, enabling them to continue their treatment regimens with fewer interruptions and a reduced risk of complications.

What Are the Current Strategies and Challenges in Chemotherapy-Induced Neutropenia Treatment?

Treatment strategies for chemotherapy-induced neutropenia focus primarily on preventing infections and supporting the patient's immune system. The most common approach involves the use of granulocyte colony-stimulating factors (G-CSFs) such as filgrastim, pegfilgrastim, and biosimilars, which stimulate the production of neutrophils in the bone marrow. These agents are typically administered as injections following chemotherapy to reduce the duration and severity of neutropenia. Antibiotic prophylaxis is another strategy used to prevent infections in patients with severe neutropenia. However, these treatments are not without challenges. G-CSF therapy can be expensive and is associated with side effects like bone pain and, in rare cases, splenic rupture. Moreover, the timing and dosage of G-CSF administration must be carefully managed to avoid complications. Additionally, not all patients respond to these treatments, and some may still experience episodes of neutropenia, requiring hospitalization and intensive care. The development of resistance to antibiotics also poses a significant challenge, underscoring the need for new therapeutic approaches and more personalized treatment strategies.

How Do Healthcare Providers Manage Chemotherapy-Induced Neutropenia in Clinical Settings?

Effective management of chemotherapy-induced neutropenia in clinical settings involves a combination of proactive monitoring, timely intervention, and patient education. Oncologists typically assess a patient’s risk of neutropenia before starting chemotherapy, considering factors such as age, overall health, and the specific type and dose of chemotherapy. For patients at high risk, prophylactic administration of G-CSFs is recommended. During treatment, patients are closely monitored through regular blood tests to track neutrophil counts and detect early signs of neutropenia. If neutropenia develops, the treatment plan may be adjusted by lowering the dose of chemotherapy or delaying subsequent cycles until the neutrophil count recovers. Infection prevention measures, including good hygiene practices, avoiding exposure to infectious agents, and patient education on recognizing early signs of infection, are critical components of care. Additionally, in cases of febrile neutropenia—a medical emergency characterized by fever and low neutrophil count—immediate hospitalization and aggressive antibiotic therapy are required to manage the condition and prevent further complications.

What Factors Are Driving the Growth of the Chemotherapy-Induced Neutropenia Treatment Market?

The growth in the chemotherapy-induced neutropenia treatment market is driven by several factors, including the increasing prevalence of cancer worldwide, which is leading to a higher demand for effective cancer treatments and supportive care therapies. Advances in chemotherapy and targeted cancer therapies, while improving survival rates, have also contributed to the increased incidence of neutropenia, necessitating more robust management solutions. The introduction of biosimilars has made G-CSF therapy more accessible and affordable, thereby expanding the market. Additionally, the growing focus on personalized medicine is driving the development of tailored treatment regimens that optimize the management of neutropenia based on individual patient risk profiles. The rise in healthcare infrastructure and access to advanced cancer care in emerging markets is also contributing to market growth, as more patients gain access to comprehensive cancer treatment, including supportive therapies like G-CSFs. Moreover, ongoing research and development efforts aimed at improving the efficacy and safety of neutropenia treatments are expected to further propel the market, offering new hope for better management of this critical chemotherapy side effect.

Select Competitors (Total 48 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â